For in vivo PDXs, afatinib also exhibited the greatest anti-tumor effects among the EGFR blockers, with a TGI of 100.22% for PDX03 and 82.65% for PDX06 (Additional file 3: Figure S1B). The gene discussed is EGFR; the disease is neoplasm.